HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

[Trend of detection of cefotaxime-resistant Escherichia coli and clinical features of bloodstream infection due to extended-spectrum β-lactamase producing Escherichia coli in a general hospital].

Abstract
Recently, the community pandemic infections of cefotaxime (CTX)-M type extended-spectrum β-lactamase (ESBL) producing bacteria, which is mostly resistant to CTX, has been well-known as major problems. When the ESBL-confirmation test cannot be done, CTX-resistant Escherichia coli might be used as the alternation method of infectious control. We investigated tendency of third-generation cephalosporin resistant E. coli and the clinical features of bloodstream infections (BSI) due to ESBL producing E. coli in our hospital, which has no department of microbial examination. We examined the trend of detection of CTX-resistant E. coli isolates from clinical samples from January 2009 to November 2013, and antimicrobial use density (AUD) of third-generation cephalosporins in the same period, and the clinical features of BSI of ESBL-producing E. coli. As a result, the percentages of CTX-resistant E. coli in all E. coli were 5.4% in inpatient and 3.9% in outpatient in 2009, but 32.8% and 17.8% in 2013, respectively. Additionally, AUD had increased from 20.6 in 2009 to 28.9 in 2013. In BSI due to E. coli, the clinical features which were male, bedridden patient and using urethral catheter, central venous catheter, chronic renal failure were significantly in the cases of ESBL-producing E. coli (n=8), compared to non-ESBL producing E. coli (n=32).
AuthorsNorihito Tarumoto, Masako Nobe, Masatsugu Uchida, Shigefumi Maesaki, Masahiko Tanaka
JournalThe Japanese journal of antibiotics (Jpn J Antibiot) Vol. 67 Issue 6 Pg. 385-93 (Dec 2014) ISSN: 0368-2781 [Print] Japan
PMID25796742 (Publication Type: Journal Article)
Chemical References
  • Anti-Bacterial Agents
  • beta-Lactamases
  • Cefotaxime
Topics
  • Anti-Bacterial Agents (pharmacology)
  • Bacteremia (microbiology)
  • Cefotaxime (pharmacology)
  • Drug Resistance, Bacterial
  • Escherichia coli (drug effects, isolation & purification)
  • Hospitals, General
  • Humans
  • Male
  • beta-Lactamases (biosynthesis)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: